ARTICLE | Clinical News
Voreloxin: Additional Phase II data
December 14, 2009 8:00 AM UTC
Additional data from the Phase II REVEAL-1 trial in 113 previously untreated patients showed that 72 mg/m 2 of IV voreloxin weekly for 3 weeks (n=29) produced a median overall survival (OS) of 8.7 mon...